FibroGen Reports Financial Results for the First Quarter of 2016
09 mai 2016 16h02 HE | FibroGen, Inc.
Continued Progress in Roxadustat Phase 3 Studies; Promising Interim Pancreatic Cancer Data –Webcast Conference Call Scheduled for 4:30pm EST Today– SAN FRANCISCO, May 09, 2016 (GLOBE NEWSWIRE)...
FibroGen to Report First Quarter 2016 Financial Results on May 9, 2016
02 mai 2016 16h05 HE | FibroGen, Inc.
SAN FRANCISCO, May 02, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel...
FibroGen Announces Publication of Phase 2 Study Results Supporting the Potential of FG-3019 to Treat Patients With Idiopathic Pulmonary Fibrosis
11 mars 2016 08h00 HE | FibroGen, Inc.
SAN FRANCISCO, March 11, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) (FibroGen) announced today that the European Respiratory Journal (“ERJ”) published on-line a manuscript...